FY2026 EPS Forecast for Dare Bioscience Raised by Analyst

Dare Bioscience, Inc. (NASDAQ:DARE – Free Report) – Brookline Capital Markets raised their FY2026 earnings per share estimates for Dare Bioscience in a research note issued on Monday, November 16th. Brookline Capital Markets analyst K. Dolliver now expects that the biotechnology company will post earnings per share of ($0.83) for the year, up from their prior estimate of ($0.92). The consensus estimate for Dare Bioscience’s current full-year earnings is ($0.74) per share. Brookline Capital Markets also issued estimates for Dare Bioscience’s Q1 2027 earnings at ($0.14) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.14) EPS and FY2027 earnings at ($0.56) EPS.

Dare Bioscience (NASDAQ:DARE – Get Free Report) last announced its quarterly earnings data on Monday, November 16th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.05). The firm had revenue of $0.05 million during the quarter, compared to the consensus estimate of $2.04 million. Dare Bioscience had a negative net margin of 748.97% and a negative return on equity of 1,052.83%.

Several other research analysts have also commented on DARE. Benchmark reiterated a “buy” rating on shares of Dare Bioscience in a research report on Monday, August 17th. HC Wainwright reiterated a “buy” rating on shares of Dare Bioscience in a report on Monday, August 17th. Weiss Ratings lowered Dare Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. UBS Group set a $1.00 price target on Dare Bioscience in a research report on Monday, September 14th. Finally, Ladenburg Thalmann & Co. Inc. assumed coverage on Dare Bioscience in a research note on Monday, October 26th. They set a “buy” rating and a $2.00 price objective on the stock. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

View Our Latest Stock Report on DARE

Dare Bioscience Stock Performance

Shares of NASDAQ DARE opened at $0.45 on Thursday. The stock’s 50 day moving average price is $0.71 and its two-hundred day moving average price is $1.49. Dare Bioscience has a 52-week low of $0.41 and a 52-week high of $3.78.

About Dare Bioscience

(Get Free Report)

Daré Bioscience is a clinical-stage biopharmaceutical company focused on developing therapies and products for women’s health. Its work spans areas including contraception, vaginal health and sexual health, with an emphasis on addressing conditions and needs that have had limited treatment options. The company’s product candidates include Ovaprene, a hormone-free, monthly-use vaginal contraceptive, and investigational treatments for conditions such as female sexual arousal disorder. These candidates remain in development and are not approved for general use.

See Also

Earnings History and Estimates for Dare Bioscience (NASDAQ:DARE)

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.